Lantheus Holdings, Inc. (LNTH) stock
LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3012% above fair value
$101.80+0.08 (+0.08%)
Close on Nov 17, 2026Market cap $6.64BP/E 24.6Yield –
Lantheus pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Lantheus's pe ratio was 24.6× on Nov 11, 2026, against 24.6× a year earlier. Over the last 5 years it ranged from 12.3× to 213.6×, with a median of 24.1×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 24.6× | −3.2 |
| 2025 | Dec 31, 2025 | 27.8× | +13.0 |
| 2024 | Dec 31, 2024 | 14.9× | −27.0 |
| 2023 | Dec 29, 2023 | 41.9× | +7.7 |
| 2022 | Dec 30, 2022 | 34.2× | −169.2 |
| 2021 | Jan 29, 2021 | 203.4× | +34.8 |
| 2020 | Dec 31, 2020 | 168.6× | +145.1 |
| 2019 | Dec 31, 2019 | 23.6× | +18.6 |
| 2018 | Dec 31, 2018 | 4.9× | −20.3 |
| 2017 | Dec 29, 2017 | 25.2× | +15.0 |
| 2016 | Dec 30, 2016 | 10.2× | – |
See a number that looks wrong?